ElevateBio Brings Centralized Model To Cell And Gene Therapy
Executive Summary
The company run by former Alexion and bluebird executives raised $150m and will build an R&D and manufacturing facility to serve its own start-ups and strategic partners, centralizing capabilities that would take individual firms millions of dollars and years to develop for a single product.
You may also be interested in...
ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
Top US FDA Official Says New 'Playbook' Needed For CMC Reviews Of Gene Therapy Products
CBER director says lack of a clear regulatory structure is holding back the development and acceleration of gene therapy products, while industry says regulations should be flexible to keep up with changing technology for these products.
Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.